skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
Analysis of tumor specimens uncovers changes in biomarker expression that may have implications for therapy selection for women with recurrent ovarian cancer
"These results demonstrate the dynamic genetic changes in ovarian
cancers between diagnosis and recurrence. While the expression of these
and other candidate response biomarkers should be evaluated in larger
studies to better understand the clinical utility of profiling recurrent
tumor specimens, this report highlights our urgent need to
individualize our treatment approaches in order to improve ovarian
cancer survival," says Dr. Karlan, Director of the Cedars-Sinai Women's
Cancer Program at the Samuel Oschin Comprehensive Cancer Institute and a
renowned expert in the field of gynecologic oncology.
".....Ovarian cancers are very different from patient to patient, which
means they are likely to respond differently to FDA-approved and
investigational drugs. By identifying the alterations in each tumor's
information pathways, molecular profiling enables the individualization
of a patient's treatment by matching those tumor alterations with one or
more drugs. The Clearity Foundation has developed a process for
generating this personalized diagnostic information using
commercially-available molecular profiling technologies and then
analyzing the results using its Diane Barton Database."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.